Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLLSNASDAQ:CNTXNASDAQ:MTEXNASDAQ:ORMP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$1.45+0.5%$1.43$1.10▼$2.81$80.43M3.11143,348 shs103,936 shsCNTXContext Therapeutics$0.59-5.1%$0.76$0.49▼$2.75$55.37M2.11291,380 shs1.04 million shsMTEXMannatech$9.86+3.7%$9.76$6.75▼$16.49$18.74M1.064,408 shs2,096 shsORMPOramed Pharmaceuticals$2.35+5.4%$2.20$1.82▼$3.09$96.00M1.65152,814 shs229,413 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis+0.49%-1.56%-12.04%+12.17%-46.80%CNTXContext Therapeutics-5.06%-15.43%-32.41%-33.98%-70.70%MTEXMannatech+6.12%+0.09%-5.66%-12.75%+28.71%ORMPOramed Pharmaceuticals+5.38%+10.85%+1.29%+12.44%+7.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLLSCellectis3.1608 of 5 stars3.55.00.00.01.92.50.6CNTXContext Therapeutics2.0333 of 5 stars3.61.00.00.02.80.01.3MTEXMannatech0.7575 of 5 stars0.04.00.00.02.21.70.0ORMPOramed Pharmaceuticals1.7701 of 5 stars0.04.00.00.02.70.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLLSCellectis 3.00Buy$7.00383.76% UpsideCNTXContext Therapeutics 3.20Buy$6.00923.89% UpsideMTEXMannatech 0.00N/AN/AN/AORMPOramed Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest MTEX, ORMP, CLLS, and CNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025CLLSCellectisBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.005/8/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/29/2025CNTXContext TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/29/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/21/2025CNTXContext TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/9/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/21/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/21/2025CNTXContext TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLLSCellectis$47.63M1.69N/AN/A$1.52 per share0.95CNTXContext TherapeuticsN/AN/AN/AN/A$0.74 per shareN/AMTEXMannatech$115.04M0.16N/AN/A$5.64 per share1.75ORMPOramed Pharmaceuticals$2M48.00N/AN/A$4.04 per share0.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLLSCellectis-$101.06M-$0.86N/AN/AN/A-234.39%-74.55%-22.65%8/5/2025 (Estimated)CNTXContext Therapeutics-$23.96M-$0.31N/AN/AN/AN/A-58.76%-55.80%8/6/2025 (Estimated)MTEXMannatech-$2.24M-$0.10N/A∞N/A-1.26%-15.62%-3.76%8/11/2025 (Estimated)ORMPOramed Pharmaceuticals$5.53M-$0.4421.36N/AN/AN/A-7.27%-6.20%8/13/2025 (Estimated)Latest MTEX, ORMP, CLLS, and CNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ORMPOramed Pharmaceuticals-$0.03-$0.19-$0.16-$0.19N/A$2.00 million5/14/2025Q1 2025CNTXContext Therapeutics-$0.05-$0.05N/A-$0.05N/AN/A5/13/2025Q1 2025MTEXMannatechN/A-$0.80N/A-$0.80N/A$26.56 million5/12/2025Q1 2025CLLSCellectis-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million3/27/2025Q4 2024ORMPOramed Pharmaceuticals-$0.03$0.01+$0.04$0.01N/AN/A3/26/2025Q4 2024MTEXMannatechN/A$1.20N/A$1.20N/A$29.01 million3/20/2025Q4 2024CNTXContext Therapeutics-$0.05-$0.04+$0.01N/AN/AN/A3/13/2025Q4 2024CLLSCellectis$0.06-$0.16-$0.22-$0.15$5.90 million$33.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLLSCellectisN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/AMTEXMannatech$0.202.03%N/AN/A N/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLLSCellectis0.481.781.78CNTXContext TherapeuticsN/A36.9136.91MTEXMannatech0.441.250.74ORMPOramed PharmaceuticalsN/A27.0827.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLLSCellectis63.90%CNTXContext Therapeutics14.03%MTEXMannatech12.98%ORMPOramed Pharmaceuticals12.73%Insider OwnershipCompanyInsider OwnershipCLLSCellectis16.41%CNTXContext Therapeutics2.80%MTEXMannatech41.50%ORMPOramed Pharmaceuticals13.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLLSCellectis29055.58 million46.46 millionOptionableCNTXContext Therapeutics789.70 million72.72 millionNot OptionableMTEXMannatech2501.90 million1.10 millionNot OptionableORMPOramed Pharmaceuticals1040.85 million34.79 millionOptionableMTEX, ORMP, CLLS, and CNTX HeadlinesRecent News About These CompaniesOramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Below 200-Day Moving Average - Should You Sell?May 28 at 3:49 AM | marketbeat.comOramed Pharmaceuticals (NASDAQ:ORMP) Stock Crosses Below 200-Day Moving Average - Should You Sell?May 27, 2025 | americanbankingnews.comOramed Pharm Extends Stock Buyback ProgramMay 21, 2025 | tipranks.comOramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.comMay 19, 2025 | marketbeat.comThe past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitableMay 17, 2025 | finance.yahoo.comStockNews.com Downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to SellMay 11, 2025 | marketbeat.comOramed Pharmaceuticals (ORMP) to Release Earnings on ThursdayMay 3, 2025 | marketbeat.comOramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau MedicalApril 28, 2025 | finanznachrichten.deAlpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed PharmaceuticalsApril 28, 2025 | globenewswire.comOramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau MedicalApril 28, 2025 | prnewswire.comORMP: Upcoming Expected Milestones Include OraTech Spin-Off & IPO, Launch of Phase 3 TrialApril 3, 2025 | finance.yahoo.comOramed Pharmaceuticals And 2 Other Penny Stocks With Promising PotentialMarch 15, 2025 | finance.yahoo.comOramed Pharmaceuticals Issues Letter to ShareholdersMarch 4, 2025 | prnewswire.comOraMed Enters Global Licensing Deal for Lidocaine ProductMarch 1, 2025 | investing.comCongressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals StockFebruary 27, 2025 | benzinga.comOramed Pharmaceuticals to Spin Off Its Protein Oral Delivery TechnologyFebruary 11, 2025 | contractpharma.comOraTech to pioneer oral insulin with $75 million investmentFebruary 11, 2025 | msn.comOramed enters JV for insulin development and commercializationFebruary 11, 2025 | markets.businessinsider.comOramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral InsulinFebruary 11, 2025 | prnewswire.comScilex announces early installment payment on senior secured promissory noteDecember 16, 2024 | markets.businessinsider.comORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent AgreementsDecember 2, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTEX, ORMP, CLLS, and CNTX Company DescriptionsCellectis NASDAQ:CLLS$1.45 +0.01 (+0.49%) Closing price 05/30/2025 03:55 PM EasternExtended Trading$1.50 +0.06 (+3.94%) As of 05/30/2025 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Context Therapeutics NASDAQ:CNTX$0.59 -0.03 (-5.06%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$0.61 +0.02 (+3.58%) As of 05/30/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Mannatech NASDAQ:MTEX$9.86 +0.35 (+3.67%) Closing price 05/30/2025 03:58 PM EasternExtended Trading$9.86 +0.00 (+0.01%) As of 05/30/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.Oramed Pharmaceuticals NASDAQ:ORMP$2.35 +0.12 (+5.38%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$2.32 -0.04 (-1.49%) As of 05/30/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
